Abstract 579: Immune features and neoantigen recognition in mismatch repair-proficient colorectal cancer liver metastases

Immunotherapy for patients with non-highly mutated, mismatch repair-proficient (MMRprof) metastatic colorectal cancer has largely been unsuccessful thus far. Here, we used transcriptomics, genomics and in vitro analyses to study the adaptive immune features of colorectal cancer liver metastases (CRL...

Full description

Saved in:
Bibliographic Details
Published in:Cancer research (Chicago, Ill.) Ill.), 2019-07, Vol.79 (13_Supplement), p.579-579
Main Authors: Hébert, Steven, Mathieu, Mélissa, Henault, David, Marques, Maud, Audemard, Éric, Courcelles, Mathieu, Brown, Scott D., Wirapati, Pratyaksha, Tejpar, Sabine, D'Angelica, Michael I., Holt, Robert A., Mader, Sylvie, Thibault, Pierre, Batist, Gerald, Kleinman, Claudia, Turcotte, Simon
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Immunotherapy for patients with non-highly mutated, mismatch repair-proficient (MMRprof) metastatic colorectal cancer has largely been unsuccessful thus far. Here, we used transcriptomics, genomics and in vitro analyses to study the adaptive immune features of colorectal cancer liver metastases (CRLMs), aiming to provide insights into the development of immunotherapies for this common malignancy. Analysis of the RNAseq data from 63 core biopsies obtained in patients enrolled in the Q-CROC-01 trial (NCT00984048) revealed 17 (27%) immune-reactive (IR) CRLMs, defined by concurrent relative high expression of antigen processing, immune cell, immune checkpoint, interferon-gamma response, cytokine, and chemokine transcripts. More T-cell receptor (TCR) sequences were found in IR vs. non-IR CRLMs (mean 89.8 ± 13.3 vs. 19.5 ± 4.0 CDR3 counts, p
ISSN:0008-5472
1538-7445
DOI:10.1158/1538-7445.AM2019-579